TDRD9 and lung carcinoma: In conclusion, our data support that TDRD9 is not only a prognosis marker in lung cancer and potentially in other types of cancer (melanoma), but also a possible therapeutic target for TDRD9-positive tumors by inhibiting its RNA helicase enzymatic activity or by blocking its TUDOR domain with specific drugs.